Compugen, Inc. provides IT products, services, and solutions for mid-to large-sized companies in Canada. It offers IT infrastructure solutions, such as Microsoft infrastructure, datacentre, print management, communications and security, virtualization, healthcare, enterprise search, storage and backup, business, networking, document output, server-based computing, and blade server solutions; IT lifecycle services; and IT optimization services, such as TCO assessments, asset management and Compugen eMerge, infrastructure maturity assessments, software license management, ITIL readiness assessments, and pandemic readiness assessments. The company also provides technical services, such as consu...
100 Via Renzo Drive
Richmond Hill, ON L4S 0B8
Founded in 1981
Compugen, Inc. Announces Establishment of Operations in South San Francisco, California; Announces Executive Appointments
Mar 28 12
Compugen Ltd. announced the establishment of operations in South San Francisco, California for the development of oncology and immunology monoclonal antibody (mAb) drug candidates against Compugen-discovered targets. The mission for Compugen Inc., a wholly owned subsidiary of Compugen Ltd., is to translate the growing portfolio of novel mAb targets being discovered and validated by the parent company into promising mAb drug candidates for licensing and partnering. The new South San Francisco Compugen Inc. operations will be located in recently secured purpose-built facilities with relevant laboratory equipment. By locating its mAb operation in the birthplace of biotech, the company gains access to some of the best biologics talent in the industry and supportive infrastructure. Furthermore, with these new capabilities, Compugen anticipates that it will significantly increase the number of mAb product candidates developed against novel Compugen-discovered targets by performing key activities more effectively and efficiently in-house compared with solely using third parties as previously intended.
The company also announced the appointment, effective April 1, 2012, of Mary Haak-Frendscho, Ph.D., as Executive Chairperson of Compugen Inc., and John J. Hunter, Ph.D., as Compugen Inc.'s Vice President of Antibody R&D and Site Head. In her role as Executive Chairperson of Compugen Inc., Dr. Haak-Frendscho will be responsible for overseeing the establishment and development of Compugen Inc.'s mAb operations. Dr. Haak-Frendscho has more than 20 years of industry experience, most recently as founding President and Chief Scientific Officer at Takeda San Francisco, Inc. John J. Hunter, Ph.D., brings to Compugen Inc. over 15 years of scientific expertise in mAb research, genomics and translational medicine. As Vice President Antibody Research and Development and Compugen Inc. Site Head, he will lead the therapeutic mAb generation and preclinical development of mAb therapeutics against Compugen-discovered targets. Prior to joining Compugen, Dr. Hunter served as a Senior Director at XOMA, managing strategic and functional activities related to building a preclinical mAb pipeline. He began his industry career at Millenium Pharmaceuticals, where he specialized in oncology therapeutics research.